The ABCs of Infant Leukemia

Current Problems in Pediatric and Adolescent Health Care

Volumn 38, Issue 3, 2008, Pages 78-94

  Zweidler McKay, Patrick A ^a   Hilden, Joanne M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Peyton Manning Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALCOHOL; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTILEUKEMIC AGENT; AZACITIDINE; BUSULFAN; CAFFEINE; CYTARABINE; DAUNORUBICIN; DIPYRONE; DOXORUBICIN; ESTROGEN; ETOPOSIDE; HERBACEOUS AGENT; INSECTICIDE; LESTAURTINIB; METHOTREXATE; METRONIDAZOLE; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; PERMETHRIN; PESTICIDE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; STEROID; TANESPIMYCIN; TIOGUANINE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BACTEREMIA; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD SAMPLING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONGENITAL DISORDER; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FETOTOXICITY; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GESTATIONAL AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFANT DISEASE; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; NEPHROTOXICITY; PHENOTYPE; PREDICTION; PRENATAL DIAGNOSIS; PREVALENCE; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UMBILICAL CORD BLOOD; UNITED STATES;

ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREGNANCY;

EID: 38949138388     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cppeds.2007.12.001     Document Type: Article

References (187)

1. Ries L., Melbert D., Krapcho M., Mariotto A., Miller B., Feuer E., et al. SEER Cancer Statistics Review, 1975-2004 Vol. 2007 (2007), National Cancer Institute, Bethesda (MD)
2. Isaacs Jr. H. Fetal and neonatal leukemia. J Pediatr Hematol Oncol 25 (2003) 348-361
3. Francis J.S., Sybert V.P., and Benjamin D.R. Congenital monocytic leukemia: report of a case with cutaneous involvement, and review of the literature. Pediatr Dermatol 6 (1989) 306-311
4. Biondi A., Cimino G., Pieters R., and Pui C.H. Biological and therapeutic aspects of infant leukemia. Blood 96 (2000) 24-33
5. Reaman G. Biology and treatment of acute leukemias in infants. In: Pui C. (Ed). Treatment of Acute Leukemias: New Directions for Clinical Research (2003), Humana Press, Totowa (NJ) 75-83
6. Reaman G., Zeltzer P., Bleyer W.A., Amendola B., Level C., Sather H., et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 3 (1985) 1513-1521
7. Pui C.H., Kane J.R., and Crist W.M. Biology and treatment of infant leukemias. Leukemia 9 (1995) 762-769
8. Dinndorf P.A., and Reaman G.H. Acute lymphoblastic leukemia in infants: evidence for B cell origin of disease by use of monoclonal antibody phenotyping. Blood 68 (1986) 975-978
9. Pieters R., Schrappe M., De Lorenzo P., Hann I., De Rossi G., Felice M., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 (2007) 240-250
10. Basso G., Putti M.C., Cantu-Rajnoldi A., Saitta M., Santostasi T., Santoro N., et al. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP). Br J Haematol 81 (1992) 184-191
11. Borkhardt A., Wuchter C., Viehmann S., Pils S., Teigler-Schlegel A., Stanulla M., et al. Infant acute lymphoblastic leukemia-combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 16 (2002) 1685-1690
12. Austin G.E., Alvarado C.S., Austin E.D., Hakami N., Zhao W.G., Chauvenet A., et al. Prevalence of myeloperoxidase gene expression in infant acute lymphocytic leukemia. Am J Clin Pathol 110 (1998) 575-581
13. Alvarado C.S., Austin G.E., Borowitz M.J., Shuster J.J., Carroll A.J., Austin E.D., et al. Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma 29 (1998) 145-160
14. Wasserman R., Galili N., Ito Y., Reichard B.A., Shane S., and Rovera G. Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event. J Exp Med 176 (1992) 1577-1581
15. Felix C.A., Reaman G.H., Korsmeyer S.J., Hollis G.F., Dinndorf P.A., Wright J.J., et al. Immunoglobulin and T cell receptor gene configuration in acute lymphoblastic leukemia of infancy. Blood 70 (1987) 536-541
16. Jansen M.W., Corral L., van der Velden V.H., Panzer-Grumayer R., Schrappe M., Schrauder A., et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 21 (2007) 633-641
17. Pui C.H., Ribeiro R.C., Campana D., Raimondi S.C., Hancock M.L., Behm F.G., et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 10 (1996) 952-956
18. Hilden J.M., Dinndorf P.A., Meerbaum S.O., Sather H., Villaluna D., Heerema N.A., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 (2006) 441-451
19. Pui C.H., Gaynon P.S., Boyett J.M., Chessells J.M., Baruchel A., Kamps W., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 (2002) 1909-1915
20. Pui C.H., Chessells J.M., Camitta B., Baruchel A., Biondi A., Boyett J.M., et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 17 (2003) 700-706
21. Dreyer Z., Dinndorf P., Sather H., Steuber C., Carroll W., Hilden J., et al. Shortened, intensified therapy in infant ALL: a Pediatric Oncology Group study (2007), American Society of Pediatric Hematology/Oncology, Toronto, Canada
22. Pieters R., den Boer M.L., Durian M., Janka G., Schmiegelow K., Kaspers G.J., et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 12 (1998) 1344-1348
23. Tomizawa D., Koh K., Sato T., Kinukawa N., Morimoto A., Isoyama K., et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 21 11 (2007) 2258-2263 Epub 2007 Aug 9
24. Gibson B.E., Wheatley K., Hann I.M., Stevens R.F., Webb D., Hills R.K., et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19 (2005) 2130-2138
25. Lie S.O., Jonmundsson G., Mellander L., Siimes M.A., Yssing M., and Gustafsson G. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 94 (1996) 82-88
26. Ross J.A., Davies S.M., Potter J.D., and Robison L.L. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev 16 (1994) 243-272
27. Webb D.K., Harrison G., Stevens R.F., Gibson B.G., Hann I.M., and Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98 (2001) 1714-1720
28. Ishii E., Okamura J., Tsuchida M., Kobayashi M., Akiyama Y., Nakahata T., et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 19 (1991) 28-32
29. Vormoor J., Ritter J., Creutzig U., Boos J., Heyen P., Ludwig W.D., et al. Acute myelogenous leukaemia in children under 2 years-experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group. Br J Cancer Suppl 18 (1992) S63-S67
30. Felix C.A., and Lange B.J. Leukemia in infants. Oncologist 4 (1999) 225-240
31. Mundschau G., Gurbuxani S., Gamis A.S., Greene M.E., Arceci R.J., and Crispino J.D. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 101 (2003) 4298-4300
32. Homans A.C., Verissimo A.M., and Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 15 (1993) 392-399
33. Al-Kasim F., Doyle J.J., Massey G.V., Weinstein H.J., and Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 24 (2002) 9-13
34. Bresters D., Reus A.C., Veerman A.J., van Wering E.R., van der Does-van den Berg A., and Kaspers G.J. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol 117 (2002) 513-524
35. Lange B. Infant AML. Am Soc Pediatr Hematol/Oncol (2007)
36. Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa III R., Patel Y., Harden A., et al. Identification of a gene. MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 88 (1991) 10735-10739
37. Cimino G., Moir D.T., Canaani O., Williams K., Crist W.M., Katzav S., et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res 51 (1991) 6712-6714
38. Djabali M., Selleri L., Parry P., Bower M., Young B.D., and Evans G.A. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2 (1992) 113-118
39. Chen C.S., Sorensen P.H., Domer P.H., Reaman G.H., Korsmeyer S.J., Heerema N.A., et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81 (1993) 2386-2393
40. Taki T., Ida K., Bessho F., Hanada R., Kikuchi A., Yamamoto K., et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 10 (1996) 1303-1307
41. Silverman L.B., McLean T.W., Gelber R.D., Donnelly M.J., Gilliland D.G., Tarbell N.J., et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 80 (1997) 2285-2295
42. Martinez-Climent J.A., and Garcia-Conde J. Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J Pediatr Hematol Oncol 21 (1999) 91-102
43. Pieters R. Biology and treatment of infant leukemias. In: Pui C. (Ed). Treatment of Acute Leukemias: New Directions for Clinical Research (2003), Humana Press, Totowa (NJ) 61-73
44. Martinez-Climent J.A., Thirman M.J., Espinosa III R., Le Beau M.M., and Rowley J.D. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. Leukemia 9 (1995) 1299-1304
45. Heerema N.A., Arthur D.C., Sather H., Albo V., Feusner J., Lange B.J., et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children's Cancer Group. Blood 83 (1994) 2274-2284
46. van der Burg M., Beverloo H.B., Langerak A.W., Wijsman J., van Drunen E., Slater R., et al. Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set. Leukemia 13 (1999) 2107-2113
47. Mathew S., Behm F., Dalton J., and Raimondi S. Comparison of cytogenetics, Southern blotting, and fluorescence in situ hybridization as methods for detecting MLL gene rearrangements in children with acute leukemia and with 11q23 abnormalities. Leukemia 13 (1999) 1713-1720
48. Hilden J.M., Frestedt J.L., Moore R.O., Heerema N.A., Arthur D.C., Reaman G.H., et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 86 (1995) 3876-3882
49. Barber K.E., Ford A.M., Harris R.L., Harrison C.J., and Moorman A.V. MLL translocations with concurrent 3′ deletions: interpretation of FISH results. Genes Chromosomes Cancer 41 (2004) 266-271
50. Harrison C.J., Griffiths M., Moorman F., Schnittger S., Cayuela J.M., Shurtleff S., et al. A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet 173 (2007) 17-22
51. Kowarz E., Burmeister T., Lo Nigro L., Jansen M.W., Delabesse E., Klingebiel T., et al. Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. Leukemia 21 (2007) 1232-1238
52. Heerema N.A., Sather H.N., Ge J., Arthur D.C., Hilden J.M., Trigg M.E., et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11)-a report of the Children's Cancer Group. Leukemia 13 (1999) 679-686
53. Pui C.H., Behm F.G., Downing J.R., Hancock M.L., Shurtleff S.A., Ribeiro R.C., et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12 (1994) 909-915
54. Moorman A.V., Raimondi S.C., Pui C.H., Baruchel A., Biondi A., Carroll A.J., et al. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia 19 (2005) 557-563
55. Satake N., Maseki N., Nishiyama M., Kobayashi H., Sakurai M., Inaba H., et al. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 13 (1999) 1013-1017
56. Pui C.H., Raimondi S.C., Srivastava D.K., Tong X., Behm F.G., Razzouk B., et al. Prognostic factors in infants with acute myeloid leukemia. Leukemia 14 (2000) 684-687
57. Lie S.O., Abrahamsson J., Clausen N., Forestier E., Hasle H., Hovi L., et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 122 (2003) 217-225
58. Rubnitz J.E., Camitta B.M., Mahmoud H., Raimondi S.C., Carroll A.J., Borowitz M.J., et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol 17 (1999) 191-196
59. Johansson B., Moorman A.V., Haas O.A., Watmore A.E., Cheung K.L., Swanton S., et al. Hematologic malignancies with t(4;11)(q21;q23)-a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 12 (1998) 779-787
60. Nagayama J., Tomizawa D., Koh K., Nagatoshi Y., Hotta N., Kishimoto T., et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood. 107 (2006) 4663-4665
61. Sorensen P.H., Chen C.S., Smith F.O., Arthur D.C., Domer P.H., Bernstein I.D., et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 93 (1994) 429-437
62. Ernst P., Wang J., and Korsmeyer S.J. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol 9 (2002) 282-287
63. Fidanza V., Melotti P., Yano T., Nakamura T., Bradley A., Canaani E., et al. Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res 56 (1996) 1179-1183
64. Corral J., Lavenir I., Impey H., Warren A.J., Forster A., Larson T.A., et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85 (1996) 853-861
65. Huret J.L., Minor S.L., Dorkeld F., Dessen P., and Bernheim A. Atlas of genetics and cytogenetics in oncology and haematology, an interactive database. Nucleic Acids Res 28 (2000) 349-351
66. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30 (2002) 41-47
67. Brown P., and Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer 40 (2004) 707-721 discussion 722-4.
68. Xu F., Taki T., Eguchi M., Kamada N., Ishii E., Endo M., et al. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. Leukemia 14 (2000) 945-947
69. Wang J., Wang T., Li S., Lin L., and Gang Y. Flt-3/ITD mutation in pediatric leukemia and its clinical significance. Ai Zheng 26 (2007) 58-63
70. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
71. Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103 (2004) 1085-1088
72. Armstrong S.A., Mabon M.E., Silverman L.B., Li A., Gribben J.G., Fox E.A., et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103 (2004) 3544-3546
73. Stam R.W., Schneider P., de Lorenzo P., Valsecchi M.G., den Boer M.L., and Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 110 (2007) 2774-2775
74. Stam R.W., den Boer M.L., Schneider P., Nollau P., Horstmann M., Beverloo H.B., et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106 (2005) 2484-2490
75. Brown P., Levis M., Shurtleff S., Campana D., Downing J., and Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105 (2005) 812-820
76. Brown P., Levis M., McIntyre E., Griesemer M., and Small D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20 (2006) 1368-1376
77. Rozovskaia T., Feinstein E., Mor O., Foa R., Blechman J., Nakamura T., et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4:11) abnormality. Oncogene 20 (2001) 874-878
78. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 (2002) 133-143
79. Milne T.A., Martin M.E., Brock H.W., Slany R.K., and Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 65 (2005) 11367-11374
80. Yu B.D., Hess J.L., Horning S.E., Brown G.A., and Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378 (1995) 505-508
81. Roche J., Zeng C., Baron A., Gadgil S., Gemmill R.M., Tigaud I., et al. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia 18 (2004) 1059-1063
82. Hess J.L., Bittner C.B., Zeisig D.T., Bach C., Fuchs U., Borkhardt A., et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 108 (2006) 297-304
83. Sun L., Heerema N., Crotty L., Wu X., Navara C., Vassilev A., et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 96 (1999) 680-685
84. Yagi T., Hibi S., Takanashi M., Kano G., Tabata Y., Imamura T., et al. High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis. Blood 99 (2002) 1350-1355
85. Ruiz A., Jiang J., Kempski H., and Brady H.J. Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B-cell survival. Br J Haematol 125 (2004) 31-37
86. Winandy S., Wu P., and Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 83 (1995) 289-299
87. Gurney J.G., Ross J.A., Wall D.A., Bleyer W.A., Severson R.K., and Robison L.L. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 19 (1997) 428-432
88. Ross J.A., and Robison L.L. MLL rearrangements in infant leukemia: is there a higher frequency in females?. Leuk Res 21 (1997) 793-795
89. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59 (1999) 4095-4099
90. Smith M.T., Wang Y., Skibola C.F., Slater D.J., Lo Nigro L., Nowell P.C., et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100 (2002) 4590-4593
91. Eguchi-Ishimae M., Eguchi M., Ishii E., Knight D., Sadakane Y., Isoyama K., et al. The association of a distinctive allele of NAD(P)H:quinone oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. Haematologica 90 (2005) 1511-1515
92. Lanciotti M., Dufour C., Corral L., Di Michele P., Pigullo S., De Rossi G., et al. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 19 (2005) 214-216
93. Garte S., Taioli E., Crosti F., Sainati L., Barisone E., Luciani M., et al. Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia. Leuk Res 24 (2000) 971-974
94. Wiemels J.L., Smith R.N., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98 (2001) 4004-4009
95. Hjalgrim L.L., Rostgaard K., Hjalgrim H., Westergaard T., Thomassen H., Forestier E., et al. Birth weight and risk for childhood leukemia in Denmark. Sweden, Norway, and Iceland. J Natl Cancer Inst 96 (2004) 1549-1556
96. Ross J.A., Perentesis J.P., Robison L.L., and Davies S.M. Big babies and infant leukemia: a role for insulin-like growth factor-1?. Cancer Causes Control 7 (1996) 553-559
97. Tower R.L., and Spector L.G. The epidemiology of childhood leukemia with a focus on birth weight and diet. Crit Rev Clin Lab Sci 44 (2007) 203-242
98. Spector L.G., Davies S.M., Robison L.L., Hilden J.M., Roesler M., and Ross J.A. Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 16 (2007) 128-134
99. Spector L.G., Xie Y., Robison L.L., Heerema N.A., Hilden J.M., Lange B., et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev 14 (2005) 651-655
100. Ford A.M., Ridge S.A., Cabrera M.E., Mahmoud H., Steel C.M., Chan L.C., et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 (1993) 358-360
101. Gale K.B., Ford A.M., Repp R., Borkhardt A., Keller C., Eden O.B., et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94 (1997) 13950-13954
102. Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol 7 (2003) 233-245
103. Hunger S.P., McGavran L., Meltesen L., Parker N.B., Kassenbrock C.K., and Bitter M.A. Oncogenesis in utero: fetal death due to acute myelogenous leukaemia with an MLL translocation. Br J Haematol 103 (1998) 539-542
104. Yeazel M.W., Buckley J.D., Woods W.G., Ruccione K., and Robison L.L. History of maternal fetal loss and increased risk of childhood acute leukemia at an early age. A report from the Children's Cancer Group. Cancer 75 (1995) 1718-1727
105. Ross J.A., Potter J.D., Shu X.O., Reaman G.H., Lampkin B., and Robison L.L. Evaluating the relationships among maternal reproductive history, birth characteristics, and infant leukemia: a report from the Children's Cancer Group. Ann Epidemiol 7 (1997) 172-179
106. Wen W., Shu X.O., Potter J.D., Severson R.K., Buckley J.D., Reaman G.H., et al. Parental medication use and risk of childhood acute lymphoblastic leukemia. Cancer 95 (2002) 1786-1794
107. Pombo-de-Oliveira M.S., and Koifman S. Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev 15 (2006) 2336-2341
108. Alexander F.E., Patheal S.L., Biondi A., Brandalise S., Cabrera M.E., Chan L.C., et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 61 (2001) 2542-2546
109. Shu X.O., Ross J.A., Pendergrass T.W., Reaman G.H., Lampkin B., and Robison L.L. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Children's Cancer Group study. J Natl Cancer Inst 88 (1996) 24-31
110. Menegaux F., Steffen C., Bellec S., Baruchel A., Lescoeur B., Leverger G., et al. Maternal coffee and alcohol consumption during pregnancy, parental smoking and risk of childhood acute leukaemia. Cancer Detect Prev 29 (2005) 487-493
111. Trivers K.F., Mertens A.C., Ross J.A., Steinbuch M., Olshan A.F., and Robison L.L. Parental marijuana use and risk of childhood acute myeloid leukaemia: a report from the Children's Cancer Group. Paediatr Perinat Epidemiol 20 (2006) 110-118 (United States and Canada)
112. Casteleyn L., and van Damme K. Pilot study on the influence of maternal and paternal occupational exposure and of other external factors on the incidence of congenital leukemia. European Commission Biomedical and Health Research Programme (1998), University of Leuven, Lueven, Belgium
113. Mangano J.J. Childhood leukaemia in US may have risen due to fallout from Chernobyl. BMJ 314 (1997) 1200
114. Pui C.H., Relling M.V., Rivera G.K., Hancock M.L., Raimondi S.C., Heslop H.E., et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9 (1995) 1990-1996
115. Felix C.A., Hosler M.R., Winick N.J., Masterson M., Wilson A.E., and Lange B.J. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85 (1995) 3250-3256
116. Pedersen-Bjergaard J., Andersen M.K., and Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 16 (1998) 1897-1898
117. Pui C.H., Relling M.V., Behm F.G., Hancock M.L., Boyett J.M., Raimondi S.C., et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9 (1995) 1680-1684
118. Aplan P.D., Chervinsky D.S., Stanulla M., and Burhans W.C. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87 (1996) 2649-2658
119. Libura J., Slater D.J., Felix C.A., and Richardson C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 105 (2005) 2124-2131
120. Moneypenny C.G., Shao J., Song Y., and Gallagher E.P. MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells. Carcinogenesis 27 (2006) 874-881
121. Ross J.A., Potter J.D., and Robison L.L. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 86 (1994) 1678-1680
122. Ross J.A. Dietary flavonoids and the MLL gene: a pathway to infant leukemia?. Proc Natl Acad Sci USA 97 (2000) 4411-4413
123. Strick R., Strissel P.L., Borgers S., Smith S.L., and Rowley J.D. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97 (2000) 4790-4795
124. van Waalwijk van Doorn-Khosrovani S.B., Janssen J., Maas L.M., Godschalk R.W., Nijhuis J.G., and van Schooten F.J. Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis 28 (2007) 1703-1709
125. Yamashita Y., Kawada S., and Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39 (1990) 737-744
126. Borkhardt A., Wilda M., Fuchs U., Gortner L., and Reiss I. Congenital leukaemia after heavy abuse of permethrin during pregnancy. Arch Dis Child Fetal Neonatal Ed 88 (2003) F436-F437
127. Ross J.A., Potter J.D., Reaman G.H., Pendergrass T.W., and Robison L.L. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control 7 (1996) 581-590
128. Ross J.A. Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors?. Int J Cancer Suppl 11 (1998) 26-28
129. Hurwitz C.A., Schell M.J., Pui C.H., Crist W.M., Behm F., and Mirro Jr. J. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Pediatr Oncol 21 (1993) 1-7
130. Creutzig U., Ritter J., and Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 75 (1990) 1932-1940
131. Woods W.G., Kobrinsky N., Buckley J.D., Lee J.W., Sanders J., Neudorf S., et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 87 (1996) 4979-4989
132. Pui C.H., Kalwinsky D.K., Schell M.J., Mason C.A., Mirro Jr. J., and Dahl G.V. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol 6 (1988) 1008-1013
133. Chessells J.M., Harrison C.J., Kempski H., Webb D.K., Wheatley K., Hann I.M., et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 16 (2002) 776-784
134. Ravindranath Y., Chang M., Steuber C.P., Becton D., Dahl G., Civin C., et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19 (2005) 2101-2116
135. Michel G., Baruchel A., Tabone M.D., Nelken B., Leblanc T., Thuret I., et al. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther 38 (1996) 169-176
136. Grier H.E., Gelber R.D., Camitta B.M., Delorey M.J., Link M.P., Price K.N., et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 5 (1987) 1026-1032
137. Hann I.M., Stevens R.F., Goldstone A.H., Rees J.K., Wheatley K., Gray R.G., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89 (1997) 2311-2318
138. Kawasaki H., Isoyama K., Eguchi M., Hibi S., Kinukawa N., Kosaka Y., et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood 98 (2001) 3589-3594
139. Palle J., Frost B.M., Forestier E., Gustafsson G., Nygren P., Hellebostad M., et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol 129 (2005) 189-198
140. Odom L.F., and Gordon E.M. Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood 64 (1984) 875-882
141. Nishikawa A., Nakamura Y., Nobori U., Aoki T., Higashino H., Matsui T., et al. Acute monocytic leukemia in children. Response to VP-16-213 as a single agent. Cancer 60 (1987) 2146-2149
142. Stam R.W., den Boer M.L., Meijerink J.P., Ebus M.E., Peters G.J., Noordhuis P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101 (2003) 1270-1276
143. Ludwig W.D., Rieder H., Bartram C.R., Heinze B., Schwartz S., Gassmann W., et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 92 (1998) 1898-1909
144. Chessells J.M., Eden O.B., Bailey C.C., Lilleyman J.S., and Richards S.M. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 8 (1994) 1275-1279
145. Reaman G.H., Sposto R., Sensel M.G., Lange B.J., Feusner J.H., Heerema N.A., et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 17 (1999) 445-455
146. Thompson P.A., Murry D.J., Rosner G.L., Lunagomez S., Blaney S.M., Berg S.L., et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 59 (2007) 847-853
147. McLeod H.L., Relling M.V., Crom W.R., Silverstein K., Groom S., Rodman J.H., et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 18 (1992) S23-S29
148. Dordelmann M., Reiter A., Borkhardt A., Ludwig W.D., Gotz N., Viehmann S., et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94 (1999) 1209-1217
149. Ishii E., Kawasaki H., Isoyama K., Eguchi-Ishimae M., and Eguchi M. Recent advances in the treatment of infant acute myeloid leukemia. Leuk Lymphoma 44 (2003) 741-748
150. Woolfrey A.E., Gooley T.A., Sievers E.L., Milner L.A., Andrews R.G., Walters M., et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 92 (1998) 3546-3556
151. Emminger W., Emminger-Schmidmeier W., Haas O.A., Urban C., Ambros P., Peters C., et al. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation. Bone Marrow Transplant 9 (1992) 313-318
152. Michel G., Leverger G., Leblanc T., Nelken B., Baruchel A., Landman-Parker J., et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 17 (1996) 191-196
153. Marco F., Bureo E., Ortega J.J., Badell I., Verdaguer A., Martinez A., et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Espanol de Trasplante de Medula Osea en Ninos. J Clin Oncol 18 (2000) 3256-3261
154. Dreyer Z., Dinndorf P., Sather H., Hilden J., Devidas M., Heerema N., et al. Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL). J Clin Oncol 25 (2007) 9514
155. Pirich L., Haut P., Morgan E., Marymount M., and Kletzel M. Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia. Med Pediatr Oncol 32 (1999) 1-6
156. Jacobsohn D.A., Hewlett B., Morgan E., Tse W., Duerst R.E., and Kletzel M. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 999-1005
157. Sanders J.E., Im H.J., Hoffmeister P.A., Gooley T.A., Woolfrey A.E., Carpenter P.A., et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 (2005) 3749-3756
158. Landier W., Bhatia S., Eshelman D.A., Forte K.J., Sweeney T., Hester A.L., et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22 (2004) 4979-4990
159. Nathan P.C., Patel S.K., Dilley K., Goldsby R., Harvey J., Jacobsen C., et al. Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: a report from the Children's Oncology Group. Arch Pediatr Adolesc Med 161 (2007) 798-806
160. Leung W., Hudson M., Zhu Y., Rivera G.K., Ribeiro R.C., Sandlund J.T., et al. Late effects in survivors of infant leukemia. Leukemia 14 (2000) 1185-1190
161. Perkins J.L., Kunin-Batson A.S., Youngren N.M., Ness K.K., Ulrich K.J., Hansen M.J., et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 49 7 (2007) 958-963 Dec
162. Mulhern R.K., Kovnar E., Langston J., Carter M., Fairclough D., Leigh L., et al. Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol 10 (1992) 1095-1102
163. Phipps S., Dunavant M., Srivastava D.K., Bowman L., and Mulhern R.K. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 18 (2000) 1004-1011
164. Oliansky D.M., Rizzo J.D., Aplan P.D., Arceci R.J., Leone L., Ravindranath Y., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 13 (2007) 1-25
165. Triplett B., Handgretinger R., Pui C.H., and Leung W. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 107 (2006) 1238-1239
166. Carroll W.L., Bhojwani D., Min D.J., Raetz E., Relling M., Davies S., et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2003) 102-131
167. Luciani M., Rana I., Pansini V., Caniglia M., Coletti V., Maraschini A., et al. Infant leukaemia: clinical, biological and therapeutic advances. Acta Paediatr Suppl 95 (2006) 47-51
168. Biondi A., Rizzari C., Valsecchi M.G., De Lorenzo P., Arico M., Basso G., et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica 91 (2006) 534-537
169. Niitsu N., Hayashi Y., Sugita K., and Honma Y. Sensitization by 5-aza-2′-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. Br J Haematol 112 (2001) 315-326
170. Stam R.W., den Boer M.L., Passier M.M., Janka-Schaub G.E., Sallan S.E., Armstrong S.A., et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 20 (2006) 264-271
171. Yao Q., Weigel B., and Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90. FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 13 (2007) 1591-1600
172. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., and Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 (2005) 207-218
173. Nakanishi H., Nakamura T., Canaani E., and Croce C.M. ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci USA 104 (2007) 14442-14447
174. Wood C.M., Goodman P.A., Vassilev A.O., and Uckun F.M. CD95 (APO-1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants. Eur J Haematol. 70 (2003) 156-171
175. Inukai T., Zhang X., Goto M., Hirose K., Uno K., Akahane K., et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 20 (2006) 2119-2129
176. Arakawa H., Nakamura T., Zhadanov A.B., Fidanza V., Yano T., Bullrich F., et al. Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene. Proc Natl Acad Sci USA 95 (1998) 4573-4578
177. Lauer S.J., Camitta B.M., Leventhal B.G., Mahoney Jr. D., Shuster J.J., Kiefer G., et al. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. J Pediatr Hematol Oncol 20 (1998) 229-233
178. Moricke A., Zimmermann M., Reiter A., Gadner H., Odenwald E., Harbott J., et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 217 (2005) 310-320
179. van Wering E.R., and Kamps W.A. Acute leukemia in infants. A unique pattern of acute nonlymphocytic leukemia. Am J Pediatr Hematol Oncol 8 (1986) 220-224
180. Park K.U., Lee D.S., Lee H.S., Kim C.J., and Cho H.I. Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. Am J Pathol 159 (2001) 2011-2016
181. Rubnitz J.E., Link M.P., Shuster J.J., Carroll A.J., Hakami N., Frankel L.S., et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 84 (1994) 570-573
182. Ludwig W.D., Bartram C.R., Harbott J., Koller U., Haas O.A., Hansen-Hagge T., et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia 3 (1989) 431-439
183. Cimino G., Rapanotti M.C., Elia L., Biondi A., Fizzotti M., Testi A.M., et al. ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res 55 (1995) 1625-1628
184. Koller U., Haas O.A., Ludwig W.D., Bartram C.R., Harbott J., Panzer-Grumayer R., et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. Leukemia 3 (1989) 708-714
185. Ferster A., Bertrand Y., Benoit Y., Boilletot A., Behar C., Margueritte G., et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 86 (1994) 284-290
186. Frankel L.S., Ochs J., Shuster J.J., Dubowy R., Bowman W.P., Hockenberry-Eaton M., et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 19 (1997) 35-42
187. Chessells J.M., Harrison C.J., Watson S.L., Vora A.J., and Richards S.M. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 117 (2002) 306-314